$BVXV News
Last published 3y ago
- 3y agoAPGEBVXVSCNIBiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsGlobeNewswireJERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai
- 3y agoBVXVBiondVax Reports Second Quarter Financial Results and Provides Business UpdateGlobeNewswireJERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic
- 3y agoBVXVNasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesGlobeNewswireJERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic
- 3y agoBVXVIBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.GlobeNewswireLOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
- 3y agoBVXVBiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisGlobeNewswireBroad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with
- 3y agoBVXVBiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateGlobeNewswireJERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 3y agoBVXVBiondVax to Present at BIO-Europe SpringGlobeNewswireJERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative
- 3y agoBVXVIBN Announces 'Test. Optimize. Scale.' Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesGlobeNewswireLOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology
- 3y agoBVXVBiondVax Presenting at BIO CEO & Investor ConferenceGlobeNewswireJERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 3y agoBVXVBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyGlobeNewswireCOVID-19 illness was virtually prevented in hamsters administered BiondVax's inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax's COVID-19 NanoAb as
- 3y agoBVXVBiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyGlobeNewswireHamsters infected with SARS-COV-2 and then treated with BiondVax's inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled
- 3y agoBVXVBiondVax to Present at Biotech Showcase 2023GlobeNewswireJERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 3y agoBVXVBiondVax CEO Issues Letter to ShareholdersGlobeNewswireJERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic
- 3y agoBVXVBiondVax Announces Closing of $8 Million Underwritten Public OfferingGlobeNewswireJERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)("Company"), a biotechnology company, which focuses on developing, manufacturing, and commercializing
- 3y agoBVXVBiondVax Announces Pricing of $8 Million Underwritten Public OfferingGlobeNewswireJERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("Company"), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic
- 3y agoBVXVIBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.GlobeNewswireLOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release
- 3y agoBVXVBiondVax Regains Nasdaq ComplianceGlobeNewswireJERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 3y agoBVXVIBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.GlobeNewswireLOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative
- 3y agoBVXVProfessor Dr. Matthias Dobbelstein joins BiondVax's Scientific Advisory BoardGlobeNewswireJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic
- 3y agoBVXVBiondVax announces Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireJERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products
- 3y agoBVXVBiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapyGlobeNewswireHamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled
- 3y agoBVXVBiondVax CEO to Present at the January 2023 Biotech Showcase in San FranciscoPR NewswireJERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic
- 3y agoBVXVBiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life SciencesGlobeNewswireJERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 4y agoBVXVBiondVax Announces Plan to Implement ADS Ratio ChangeGlobeNewswireJERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative
- 4y agoBVXVBiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 ConferencePR NewswireJERUSALEM, Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the
- 4y agoBVXVBiondVax provides plan to address Nasdaq compliancePR NewswireJERUSALEM, Nov. 2, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the
- 4y agoBVXVBiondVax to present at LD Micro Investor Conference in Los AngelesPR NewswireJERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the
- 4y agoBVXVBiondVax announces financial plans to support its ongoing NanoAb pipeline developmentPR NewswireJERUSALEM, Israel , Sept. 30, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infect
- 4y agoBVXVBiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19PR NewswireJERUSALEM, Sept. 20, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today p
- 4y agoBVXVBiondVax to Present at H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireJERUSALEM, Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVBiondVax announces Second Quarter 2022 Financial Results and Provides Business UpdatePR NewswireJERUSALEM, Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today pu
- 4y agoBVXVBiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategyPR NewswireJERUSALEM, Aug. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative biological medicinal products for the prevention and treatment of infe
- 4y agoBVXVBiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trialPR NewswirePEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax's clinical development timelines for its first NanoAb product, a COVID-19
- 4y agoBVXVBiondVax Announces First Quarter 2022 Financial Results and Provides Business UpdatePR NewswireJERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and o
- 4y agoBVXVBiondVax to Present at H.C. Wainwright Global Investment ConferencePR NewswireJERUSALEM, May 19, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and othe
- 4y agoBVXVBiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies ProgramPR NewswireJERUSALEM, May 12, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and othe
- 4y agoBVXVBiondVax to Present at this week's Biomed Israel ConferencePR NewswireJERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVBiondVax to host a Hebrew-language analyst and investor webinar on April 6thPR NewswireJERUSALEM, April 5, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and oth
- 4y agoBVXVBiondVax to host analyst and investor webinar on April 4thPR NewswireJERUSALEM, March 31, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVGSKBiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatePR NewswireJERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVHEPSNKLASPPI+1Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?PR NewswireNEW YORK, March 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, HEPS, BVXV, TCOM, and SPPI.
- 4y agoBVXVBiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapiesPR NewswireJERUSALEM, March 24, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVEuropean Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New StrategyPR NewswireJERUSALEM, March 14, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced today that it had been negotiating with the European Investment Bank (the "EIB") terms of restructuring of its outstanding €24 million loan (the "Loan"). T
- 4y agoBVXVBiondVax to Present at Aegis Virtual ConferencePR NewswireJERUSALEM, Feb. 22, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVBiondVax to Present at BIO CEO & Investor ConferencePR NewswireJERUSALEM, Feb. 15, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and ot
- 4y agoBVXVBiondVax to Present at Edison Group's Open House ConferencePR NewswireJERUSALEM, Jan. 26, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and oth
- 4y agoBVXVBiondVax to Present at H.C. Wainwright Bioconnect Virtual ConferencePR NewswireJERUSALEM, Jan. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and oth
- 4y agoBVXVAegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)ACCESS NewswireNEW YORK, NY / ACCESSWIRE / January 3, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). About BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceutic
- 4y agoARDSBVXVKPRXNAKD+1Thinking about buying stock in Reliance Global, Naked Brand, Kiora Pharmaceuticals, Aridis Pharmaceuticals, or Biondvax Pharmaceuticals?PR NewswireNEW YORK, Dec. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RELI, NAKD, KPRX, ARDS, and BVXV.
- 4y agoBVXVBiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-AllotmentPR NewswireJERUSALEM, Dec. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and o